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ABSTRACT
The discovery of broadly neutralizing antibodies
(bNAbs) has provided an enormous impetus to the
HIV vaccine research and to entire immunology.
The bNAber database at http://bNAber.org provides
open, user-friendly access to detailed data on the
rapidly growing list of HIV bNAbs, including neutral-
ization profiles, sequences and three-dimensional
structures (when available). It also provides an exten-
sive list of visualization and analysis tools, such as
heatmaps to analyse neutralization data as well as
structure and sequence viewers to correlate bNAbs
properties with structural and sequence features of
individual antibodies. The goal of the bNAber
database is to enable researchers in this field to
easily compare and analyse available information
on bNAbs thereby supporting efforts to design an
effective vaccine for HIV/AIDS. The bNAber
database not only provides easy access to data
that currently is scattered in the Supplementary
Materials sections of individual papers, but also con-
tributes to the development of general standards of
data that have to be presented with the discovery of
new bNAbs and a universal mechanism of how such
data can be shared.
INTRODUCTION
Broadly neutralizing antibodies (bNAbs) neutralize
multiple viral strains, in contrast to non-cross-reactive
antibodies that are specific for individual strains. Their dis-
covery changed our views of how humans can deal with
quickly mutating viruses, such as HIV, influenza and
hepatitis C, and is one of the most exciting discoveries in
immunology in the last several years. Among other new
discoveries, bNAbs have opened new avenues in the quest
for the development of a vaccine against HIV/AIDS, as
bNAbs against antigens such as HIV envelope glycoprotein
(Env) can be used as templates for the design of vaccines
(1). Following on this promise, the number of groups
working on identifying new HIV bNAbs and the number
of known antibodies started to grow rapidly. Several large
studies now in development guarantee even faster growth
in incoming years. However, at this point, detailed infor-
mation on newly identified bNAbs is available only in
supplementary materials of individual papers, with no
common resource collecting all available information on
HIV bNAbs and no general standards about what set of
data should be presented for each new antibody.
For example, both the number and clade composition
of viral strains used to calculate neutralization data (IC50
and IC80) and even the precise definition of when an
antibody can be called broadly neutralizing vary from
study to study (2). Different assay protocols or different
virus panels can give different results. For one antibody
(2F5), different studies reported the breadth of neutraliza-
tion being between 39% and 67%, as different studies
used different neutralization panels (3–5). Compounding
these inconsistencies is the fact that there is no single
resource that collects information about HIV specific
bNAbs. Some data are available from the IEDB-3D
epitope database (6) and LANL’s HIV Molecular
Immunology Databases (7), via the ‘Neutralizing
Antibody Resources’ page in the Immunology section at
http://www.hiv.lanl.gov/. IEDB-3D provides data on HIV
antibodies with experimentally determined structures but
has no data about neutralization breadth and efficiency
and, more importantly, it does not present any informa-
tion on antibodies without experimental structures (6).
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The LANL resource offers a ‘Summary of Best
Neutralizing Antibodies’ table with links to papers, Ab
sequences and structures, notes on breadth of neutraliza-
tion, and references to the tables and figures in original
publication, as well as list of Ab contacts or key residues.
Actual neutralization data, however, are not available,
making it difficult for the neutralization profiles of differ-
ent antibodies to be compared, and difficult to perform
any kind of comparative analysis of bNAbs without col-
lecting needed information from primary literature. Also,
neither IEDB-3D nor LANL’s ‘Neutralizing Antibody
Resources’ have mechanisms for submitting data on new
bNAbs.
bNAber (short for broadly Neutralizing Antibodies
electronic resource) provides access to raw data on
broadly neutralizing HIV antibodies, including sequences,
structures and neutralization IC50 data, as well as in-
house and third party software to analyse it. Its ultimate
goal is to support immunogen design for the development
of an HIV/AIDS vaccine. Although bNAber database is
primarily addressed to AIDS research community, we
expect that the general importance of the bNAb field
will entice interest from much broader group of
researchers. bNAber is freely available at http://bNAber.
org and does not require any login or registration.
DATA INTEGRATION AND CURATION
Two types of HIV can be distinguished genetically and
antigenically: HIV-1 is the cause of the current worldwide
pandemic, whereas HIV-2, found mostly in West Africa, is
less easily transmitted and is not considered a worldwide
health risk. More than 90% of HIV/AIDS cases are
caused by infection with HIV-1 viruses group M, the
most common type of HIV (8). The M group is subdivided
further into clades, called subtypes that are also given a
letter.
The HIV neutralization is currently tested in the TZM-
bl/pseudovirus assay (5). This assay measures neutraliza-
tion in TZM-bl cells as a function of a reduction in
Tat-induced luciferasereporter gene expression after a
single round of virus infection. There is no standard
accepted percent cutoff used for bNAbs definition, but
most of bNAbs described in literature neutralize at least
30% of strains in large TZM-bl panels (more than 100
HIV strains). The neutralization breadth is defined as %
of strains neutralized by this Ab. The median antibody
concentrations required to inhibit HIV activity by 50%
(IC50) is referred to as neutralization ‘potency’ or ‘depth’.
The bNAber database schema was developed by
combining fields from data tables in Walker et al. (2)
with fields used in LANL table ‘Summary of Best
Neutralizing Antibodies’, additional fields were suggested
by the database beta testers from the Scripps CHAVI-ID
groups. Data on a set of currently known 60 HIV
bNAbs were downloaded from the LANL HIV, PDB
and GenBank databases and converted into bNAber
database tables. The tables were further carefully
curated with data manually extracted from individual
papers, listed in the Supplementary On-line Materials.
Raw data on neutralization were parsed from
supplementary materials of manuscripts describing indi-
vidual bNAbs and loaded into the database. A continu-
ously updated list of papers used as a source of data for
bNAber are provided as part of the Online-only
Supplementary Data. All imported data were carefully
curated prior to loading into the database, including
fixing erroneous or non-standard bNAb and virus strain
names. An automated pipeline will be developed to ease
the database updates.
WALK THROUGH THE DATABASE AND TOOLS
The bNAber home page provides an interface to access all
of the database content. There, a user can select individual
antibodies or groups of them for further analysis by
different criteria including donor, study, neutralization
breadth (% of strains neutralized with IC50 or
IC80< 50 mg/ml) and depth (median IC50 (mg/ml)
against viruses neutralized with an IC50< 50 mg/ml).
Selection by epitope can be done both from a drop-
down menu and from a graphical interface of the HIV
spike protein model. After selection, clicking the
‘submit’ button opens up a summary page of selected
antibodies and a drop-down menu allowing the user to
select further actions. On the summary page, clicking on
underlined names of specific antibodies opens individual
pages with full information about each antibody in the
database (see Figure 1 for a sample series of steps
through the main pages of the database). The antibody
details page combines data on neutralization efficiency
(median IC50 (mg/ml) against viruses neutralized with an
IC50< 50 mg/ml) from all available studies. In addition,
links with PDB codes of coordinates (when available)
provide access to an integrated Jmol (9) structure
viewer, which allows researchers to view complex struc-
tures, including precalculated antibody–antigen binding
sites (epitope on antigen and paratope on Ab). This func-
tionality is discussed in greater detail in the Online
Supplementary Data (Supplementary Figures S1–S3).
Five actions highlighted in the pull-down menu from the
summary page are available in the current bNAber release,
others are in development and the date of their availability
is indicated on the menu. Three of the actions, ‘Show se-
quences and download FASTA file’, ‘Percent viruses
neutralized with an IC50< 50 mg/ml, per clade’ and
‘Median IC50 (mg/ml) against viruses neutralized with an
IC50< 50 mg/ml, per clade’ are simple and self-explanatory.
The third one, ‘Overlay structures’, links to a POSA server
(10) for multiple structure analysis, which is discussed
below. The action ‘Show aligned sequences’ leads to the
page which presents aligned Abs amino acid sequences
and allows a user to perform further sequence analysis by
tools such as Jalview (11).Using Jalview, a user can color se-
quence alignments, build phylogenetic trees and correlate
Abs sequence similarity with their neutralizing properties
(e.g., by comparing trees with clustered heatmaps ob-
tained from the next tab, as described below).
In addition, navigation tabs on the home page provide
access to other features and functionalities of the database.
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Neutralization heatmaps
This tab provides access to an interface for clustering of
the neutralization data based on the similarity of neutral-
ization IC50 values against individual virus strains.
Heatmaps are popular tools to present matrices with
large amount of data in a convenient, compact form.
Heatmaps of hierarchically clustered data can be used to
assess similarity and differences of objects (Abs and virus
strains in our case), to find the number of distinct groups
of objects, and to correlate the grouping of objects with
their other properties. This tool can help a user answer
questions such as comparing neutralization data for
several Abs to determine differences and similarities in
their behavior relative to particular virus clade or strain,
comparing neutralization data obtained in different
studies, or compare and correlate grouping of bNAbs
based on neutralization properties and on sequence simi-
larity, epitope or other features. Neutralization data can
be presented in two forms: numerical colored table, such
as found in papers describing neutralization data, and
heatmaps. Browsing large neutralization tables require
scrolling through the page, but a heatmap view of neutral-
ization table allows large datasets to be easily viewed on
one screen (Figure 2). Hierarchical clustering in turn helps
researchers show groups, similarities and differences in the
neutralization data of several antibodies tested on large
panels of HIV strains (Figure 2). The heatmap is
generated using the Euclidean distance and average-
linkage clustering method and the log10 values of the
IC50 neutralization data for a subset of virus strains
(utilizing an IC50 of 50 mg/ml for values designated as
>50 mg/ml) and bNABs that are displayed on the axes.
POSA multiple structure comparisons
This tab brings the user to the POSA server (10) page with
precalculated results of structure alignments of all pairs of
HIV bNAb structures and an interface to perform further
analysis. The POSA server for multiple protein structure
alignment by partial order graphs was developed
previously in our group and provides several tools and
interfaces to study structural similarity and diversity
between homologous proteins (10). The superposition is
driven by the structural alignment of selected chains—it
can be an antigen or Heavy or Light chain of an antibody.
At the next step, other chains are superimposed using the
same transformation matrix and root mean square devi-
ation is calculated for all equivalent C-alpha atoms. This
approach can identify even subtle differences in the
binding mode of the antibody and the antigen. The inter-
face presents the aligned sequences and structures in
multiple windows, making it easy for users to analyse
and compare the structures of antibody–antigen
complexes. Independently, access to the precalculated
results and to the POSA interface is available from a
pull-down menu on the summary pages available from
the home page followed by manual selection of specific
coordinate sets (see the Discussion section below). Pairs
and groups (up to five) of antibodies can be selected and
their multiple structure alignment can be analysed by the
POSA visual interface. Structure comparisons are
Figure 1. The primary access mode to the bNAber database, from selection of a subset of antibodies on the home page to the summary page for the
selected antibodies to the dedicated antibody page.
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presented using a novel, multi-window display of protein
complexes. Figure 3 shows an example of POSA structure
comparisons of bNAbs complexes PDB:2NY7 and
PDB:3U7Y aligned on the antigen structure.
Submit new bNAb
This tab provides an interface for easy input of data
(Supplementary Figure S4, see Supplementary Data) on
a new bNAb. The suggested list of features is based on the
recently published bNAb discovery papers and LANL
table ‘Summary of Best Neutralizing Antibodies’. For
large-scale neutralization studies we invite researchers to
submit data tables (through the provided interface), which
we will upload into the database. Before submission, the
form will be validated for required fields as well as for
expected values (e.g., neutralization data should be non-
negative). Once the form has been validated, the submitted
data are put into a temporary holding area, which is peri-
odically validated by the annotator. Once the annotator
and the bNAber team have validated that the data are a
genuine scientific contribution, the data are sanitized
against MySQL injection attacks and inserted into the
database, at which point the new data are automatically
displayed on the bNAber web application.
Biologist view
bNAber provides multiple menu driven interfaces and an
option to submit user-edited SQL queries (in develop-
ment). However, we anticipate that many users will have
limited experience in using on-line databases and in this
tab we provide access to several queries defined by specific
user questions. Clicking on a specific question on the list
brings the users to a dedicated query designed to answer
this question. We have polled the beta testers of the
bNAber database about questions they would like to
have answered. bNAber team invites users to provide us
with additional questions.
Help, use cases and database download
Access to general help, including links to several
precalculated examples, database tutorial and on-line
Supplementary Material are provided in this tab. ‘Use
cases’ section has step-by-step instructions on how to
perform several typical database tasks, including
Figure 2. Heatmap neutralization data for selected bNAbs (IC50 in mg/ml) shown in alphabetical order (top panel) and ordered by hierarchical
biclustering of the IC50 neutralization data (bottom panel) for the same subset of virus strains (log10 of IC50 data were used, with IC50 >50 mg/ml
replaced by 50). See On-line Supplementary Data for references to tools used to create this image.
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Figure 3. POSA structural superposition of two antibody–antigen complexes, 3U7Y (NIH45-46 Fab in complex with gp120 of strain 93TH057
HIV-1) and 2NY7 (Broadly Neutralizing CD4-Binding-Site Antibody b12 and gp120) with primary alignment on the antigen gp120 chains. The
superposition illustrates the difference between the two antibodies bound to the same epitope, but at different angles relative to the gp120 surface.
Separate windows below allow for separate viewing of individual antibodies.
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comparing median IC50 neutralization data of two
bNAbs in different studies. Additionally, an option to
export the bNAbs database is available here. An option
to download specific tables and data for subsets of bNAbs
is also available on some pages.
DISCUSSION
The ultimate goal of the bNAber database is to support
immunogen design for HIV/AIDS vaccine development
by providing easy access to data on all known HIV
bNAbs and facilitating their analysis. Understanding the
relation between molecular data on neutralizing Abs, Env
and structure of Ab–Env complexes should facilitate the
generation of antigens presenting protective epitopes (1).
By developing bNAber we aimed to integrate publicly
available, but dispersed data on HIV bNAbs into a
single database with a unified interface. bNAber
provides detailed information on all known HIV
bNAbs, including raw neutralization data from TZM-bl
assay, sequences of bNAbs, when available, activity
against alanine mutants, predicted epitopes, and 3D struc-
tures of bNAbs and their complexes with antigens.
Neutralizing activity of bNAbs against pseudovirus
panels is used to compute median IC50 and percent of
viruses neutralized for full panels or their subsets, thus
opening the way to compare data from different labs or
panels.
Data in bNAber are available using a series of user-
friendly interfaces designed to support typical search
strategies. Users have multiple ways of selecting
antibodies for comparative analysis, including study, rec-
ognition site (gp160 epitope), donor and breadth or depth
of neutralization (high or low). Presenting data for a
selected group of bNAbs provide a convenient way to
understand the antibody properties important for
immunogen design. Multiple analysis types applicable to
the selected groups of bNAbs, including multiple sequence
and pairwise structure alignments, neutralization
heatmaps and others are available from the pull-down
menus. The 3D information, including precalculated
structure comparisons of bNAbs, is presented using a
novel, multi-window display of protein complexes. This
display provides researchers with a convenient way to
explore the binding modes of the various antibodies and
compare different conformations of the same antibody.
bNAber differs significantly from other HIV antibody
databases. IEDB is an epitope-centric resource and
contains information on anti-HIV antibodies which struc-
tures are available in PDB in complexes with antigens.
bNAber focuses on multiple data types on broadly
neutralizing HIV Ab and provides information on Ab
without structures as well. At the same time bNAber has
less structures then IEDB because it concentrates only on
bNAbs. Examples of HIV antibodies that were not con-
sidered for inclusion in the resource: N5-i5 Fab (3TNN),
13H11 Fab fragment (3MO1, 3MNW, etc.) or N12-i15
(3QEH, 3TMN, 3TNN). bNAber in comparison with
LANL’s HIV Molecular Immunology Database provides
access to bNABs aligned sequences, structures, raw neu-
tralization data and integrated analysis tools.
The information in the database is currently extracted
manually from literature, including supplemental
material, and additional information is downloaded
from the LANL HIV Molecular Immunology Database,
PDB and GenBank. We believe that the basic data struc-
ture in the bNAber database can serve as a prototype for a
standard set of data that minimally should be submitted
when new bNAbs are discovered. Therefore, we ultimately
intend to rely on community data depositions, especially
depositions accompanying paper publications. To this
end, we provide a separate interface for outside users to
submit data, either entered manually or uploaded to the
database.
We will work with the AIDS community and NIH to
develop a mechanism for direct deposition of data on new
bNAbs accompanying new publications to bNAber. Such
mechanism may eventually replace the current system of
providing information on bNAbs in supplementary data,
which uses different standards and is generally not com-
patible between different journals.
The bNAber database was created for the users who
want to: (i) analyse in details sequence, 3D structure, neu-
tralization profiles, escape mutations, etc. of anti-HIV
Abs; (ii) design, synthesize and express genes coding new
immunogens aiming to elicit bNAbs; (iii) analyse 3D
features of broad neutralization; (iv) sequence antibody
genes in immunized animal/patient and track the develop-
ment of the Ab genes leading to broad neutralization; and
(v) correlate features of sequence and structure of Abs
with their ability to cross-neutralize. The resource could
be of interest to researchers developing vaccines to other
diseases, including influenza, hepatitis C, dengue and West
Nile viruses (12).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online,
including [2,13–23].
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